NEULANDLAB

Neuland Laboratories Share Price

₹10,995.50 -416.8 (-3.65%)

22 Feb, 2025 23:13

SIP TrendupStart SIP in NEULANDLAB

Start SIP

Performance

  • Low
  • ₹10,950
  • High
  • ₹11,472
  • 52 Week Low
  • ₹5,540
  • 52 Week High
  • ₹18,100
  • Open Price₹11,470
  • Previous Close₹11,412
  • Volume32,287

Investment Returns

  • Over 1 Month -16.84%
  • Over 3 Month -25.55%
  • Over 6 Month -4.85%
  • Over 1 Year + 51.22%
SIP Lightning

Smart Investing Starts Here Start SIP with Neuland Laboratories for Steady Growth!

Invest Now

Neuland Laboratories Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 47
  • PEG Ratio
  • -8.7
  • Market Cap Cr
  • 14,107
  • P/B Ratio
  • 10.1
  • Average True Range
  • 780.65
  • EPS
  • 187.04
  • Dividend Yield
  • 0.1
  • MACD Signal
  • -465.27
  • RSI
  • 29.52
  • MFI
  • 22.81

Neuland Laboratories Financials

Neuland Laboratories Technicals

EMA & SMA

Current Price
₹10,995.50
-416.8 (-3.65%)
pointer
  • stock-down_img
  • Bullish Moving Average 0
  • stock-up_img
  • Bearish Moving Average 16
  • 20 Day
  • ₹12,748.06
  • 50 Day
  • ₹13,513.80
  • 100 Day
  • ₹13,405.38
  • 200 Day
  • ₹11,964.34

Resistance and Support

11139.17 Pivot Speed
  • R3 11,850.33
  • R2 11,661.17
  • R1 11,328.33
  • S1 10,806.33
  • S2 10,617.17
  • S3 10,284.33

What's your outlook on Neuland Laboratories?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Neuland Laboratories is a leading pharmaceutical company specializing in the manufacturing of active pharmaceutical ingredients (APIs) and custom manufacturing solutions. It serves global pharmaceutical companies with high-quality APIs for critical therapeutic areas, including cardiovascular and central nervous system.

Neuland Laboratories has an operating revenue of Rs. 1,533.49 Cr. on a trailing 12-month basis. An annual revenue growth of 31% is outstanding, Pre-tax margin of 26% is great, ROE of 23% is exceptional. The company has a reasonable debt to equity of 4%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 84 which is a GOOD score indicating consistency in earnings, a RS Rating of 82 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at E which indicates heavy supply, Group Rank of 67 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of B is close to being the best. Overall, the stock has great fundamentals and relative strength but it needs to see some buyer interest to stay in momentum.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Neuland Laboratories Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-02-10 Quarterly Results
2024-11-06 Quarterly Results
2024-08-01 Quarterly Results
2024-05-10 Audited Results & Final Dividend
2024-02-08 Quarterly Results
Date Purpose Remarks
2022-07-15 FINAL Rs.5.00 per share(50%)Final Dividend

Neuland Laboratories F&O

Neuland Laboratories Shareholding Pattern

32.68%
6.29%
0.57%
23.86%
26.04%
10.56%

About Neuland Laboratories

  • NSE Symbol
  • NEULANDLAB
  • BSE Symbol
  • 524558
  • ISIN
  • INE794A01010

Similar Stocks to Neuland Laboratories

Neuland Laboratories FAQs

Neuland Laboratories share price is ₹10,995 As on 22 February, 2025 | 22:59

The Market Cap of Neuland Laboratories is ₹14107.1 Cr As on 22 February, 2025 | 22:59

The P/E ratio of Neuland Laboratories is 47 As on 22 February, 2025 | 22:59

The PB ratio of Neuland Laboratories is 10.1 As on 22 February, 2025 | 22:59

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23